The abstract is read at the publisher; the summary is JClub's.
In human prostate cancer, USP8 inhibition suppresses RICTOR/mTORC2 signaling by inducing RICTOR degradation, producing marked tumor suppression in vivo.
- Why it matters: RICTOR is crucial for mTORC2 activity, yet how it becomes aberrantly activated in prostate cancer is unclear, limiting targeted therapeutic options.
- What they did: The study mapped RICTOR as a Cullin 3–SPOP substrate and identified USP8 as the upstream deubiquitinase; USP8 inhibition was tested for effects on mTORC1 versus mTORC2 and for tumor outcomes in vivo.
- The result: SPOP deficiency or cancer-derived SPOP mutations disrupt RICTOR degradation, promoting progression, while USP8 inhibition specifically suppresses RICTOR/mTORC2 without affecting mTORC1 and enables tumor suppression in vivo.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.